Moderna Omicron vaccine effective against BA.4/5 Omicron variants
- Aspirin: Study Finds Greater Benefits for These Colorectal Cancer Patients
- Cancer Can Occur Without Genetic Mutations?
- Statins Lower Blood Lipids: How Long is a Course?
- Warning: Smartwatch Blood Sugar Measurement Deemed Dangerous
- Mifepristone: A Safe and Effective Abortion Option Amidst Controversy
- Asbestos Detected in Buildings Damaged in Ukraine: Analyzed by Japanese Company
Moderna Omicron vaccine effective against BA.4/5 Omicron variants
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
Moderna Omicron vaccine effective against BA.4/5 Omicron variants.
Moderna announced today that its bivalent vaccine, the original wild-type and Omicron BA.1 mixed vaccine mRNA-1273.214, was boosted with 50ug mRNA-1273.214 on the basis of 2 doses of the original vaccine mRNA-1273.
Compared with before booster vaccination with mRNA-1273.214, the neutralizing activity of BA.4/5 increased by 5.4 times and increased by 6.3 times in virus-naïve patients.
However, the neutralizing titer of serum for BA.4/5 was 3 times lower than for BA.1. In this Phase 2/3 clinical trial of 800 people, one month after inoculation with mRNA-1273.214, the serum neutralization titer for BA.4/5 was 941, compared with 3 doses of mRNA-1273.
BA.1 neutralizing activity was 629. It can be seen that mRNA-1273.214 has good immunogenicity and is very effective against the Omicron subtype. The company is currently applying for an EUA for the vaccine for listing.
Moderna bivalent vaccine triggers potent neutralizing antibodies to BA.4/BA.5.
On June 22, 2022 , Moderna once again announced the latest clinical data of the COVID-19 original strain/Omicron bivalent vaccine- mRNA-1273.214 in the Phase 2/3 clinical trial. 50ug of mRNA-1273.214 was re-vaccinated in the population that completed the mRNA-1273 prime and booster immunizations.
One month later, mRNA-1273.214 could trigger potent neutralizing antibodies to BA.4/BA.5 regardless of past infection history with COVID-19.
The clinical data obtained yesterday showed that the mRNA-1273.214 booster injection can increase the neutralizing antibody titer of the subjects’ serum to BA.4/BA.5 by 5.4 times , regardless of whether there is a history of past infection with the COVID-19 ; In test subjects ( without previous infection ), the mRNA-1273.214 booster can increase the neutralizing antibody titer of serum to BA.4/BA.5 by 6.3 times.
On June 8, Moderna announced that the mRNA-1273.214 booster injection could increase the neutralizing antibody titer of COVID-19 seronegative subjects to Omicron/BA.1 by 8 times, and the average Omicron neutralizing antibody titer was 2372.
The data this time shows that one month after inoculation with the mRNA-1273.214 booster needle, regardless of whether there was a past infection, the average BA.4/BA.5 neutralizing antibody titer of all subjects was 941, while the COVID-19 seronegative subjects The average titer of neutralizing antibody to BA.4/BA.5 was 727.
It can be seen from the above data that the neutralizing antibody titer targeting BA.4 /BA.5 in the serum of the mRNA-1273.214 booster subjects was about 3 times lower than that targeting BA.1 .
The data on June 8 showed that among the COVID-19 seronegative subjects, the serum neutralizing antibody titers targeting Omicron/BA.1 triggered by the mRNA-1273.214 booster injection were higher than those triggered by the mRNA-1273 booster injection. out about 1.6 times .
The neutralizing antibody titers of the targeted primary strain ( D614G ) triggered by the mRNA-1273.214 booster were 1.2 -fold higher than those triggered by the mRNA-1273 booster .
From these data, it can be seen that as the original strain/Omicron bivalent COVID-19 vaccine, mRNA-1273.214 as a booster trigger has better neutralizing antibody titers than mRNA-1273 .
In addition, the mRNA-1273.214 bivalent vaccine is similar to the mRNA-1273 original strain vaccine in terms of tolerability and safety.
In addition, in April this year, Moderna also announced the clinical phase 2/3 data of the bivalent vaccine mRNA-1273.211, with doses of 50ug and 100ug, containing half of Spike-WT mRNA and half of Spike-Beta mRNA.
After the initial immunization with mRNA-1273, the titer of neutralizing antibody targeting Omicron/Delta/Beta triggered by the third booster mRNA-1273.211 was 1.2-2.74 times higher than that of mRNA-1273.
So far, the Phase II clinical trial data of Moderna’s two bivalent vaccines, mRNA-1273.211 and mRNA-1273.214, have been obtained.
Detailed data on mRNA-1273.211 was published in April, while detailed clinical data on mRNA-1273.214 are being submitted for publication.
Several recent studies have confirmed that the antigenic distance between Omicron and the original strain is very different.
Using the bivalent vaccine combination of the original strain antigen + Omicron antigen, the broad spectrum of serum antibodies triggered will be better .
Coupled with the recent increase in the proportion of BA.4/BA.5 infections ( according to the latest data released by the US CDC, as of June 18, 2022, the new coronavirus Omicron BA.4/5 mutant strain has accounted for the COVID-19 infection in the United States. 42.5% ) and immune escape from natural infection with BA.1, mRNA-1273.214 can trigger potent neutralizing antibodies to BA.4/BA.5 will be a huge advantage in its launch.
Moderna Omicron vaccine effective against BA.4/5 Omicron variants
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
